siRNA 접합체 시장 : 치료 분야별, 개발 단계별, 접합체 유형별, 최종사용자별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율, 예측(2026-2033년)

siRNA Conjugates Market size was valued at US$ 810.71 Million in 2025, expanding at a CAGR of 15.10% from 2026 to 2033.

siRNA conjugates are special treatments that attach small interfering RNA (siRNA) to molecules that help deliver it into cells. This makes the RNA more stable, easier to target, and better absorbed by cells. They allow scientists to turn off specific genes to treat different diseases more effectively, with fewer side effects. The market for these therapies is growing because of better delivery methods, more research in RNA-based treatments, and increased investment in precision medicine.

The siRNA conjugates market is expanding in delivery technologies and a rising need for precise, targeted treatments. These conjugates transport small interfering RNA directly to specific cells, allowing genes to be silenced accurately to treat various diseases. Better stability, improved targeting, and enhanced cellular uptake make these therapies more effective and safer, improving treatment outcomes and minimizing side effects. In 2025, Alnylam Pharmaceuticals, Inc. announced a major expansion of its U.S. manufacturing footprint with a $250 million investment to build dedicated siRNA drug production capabilities, aimed at enhancing precision and speed in delivering its RNAi therapeutics to patients, reflecting growing demand for targeted gene-silencing treatments. These advances underscore the growing adoption of siRNA conjugates in precision medicine.

siRNA Conjugates Market- Market Dynamics

Increasing Awareness About Targeted Therapies To Propel Market Demand

One primary driver of the growing demand for targeted therapies is fueled by the increasing use of advanced drug delivery platforms, precision medicine strategies, and next-generation biologics such as siRNA conjugates and antibody-drug conjugates. Recent advances include targeted small-molecule inhibitors, novel immune checkpoint and antibody-drug conjugates, and AI-driven tools to speed drug discovery. These trends aim to minimize side effects, improve patient outcomes, and support a modern, technology-driven healthcare landscape. In late 2025 and early 2026, Alnylam Pharmaceuticals, Inc. continued to advance its RNAi therapeutic platform, reporting financial results for 2025 that included robust growth in product revenues and outlining 2026 pipeline goals with multiple clinical readouts and new study initiations as part of its strategy to deliver targeted RNA interference treatments for genetic and other diseases. These developments underscore siRNA conjugates' growing role in precision medicine, driven by innovation, clinical advances, and safer, more effective therapies.

siRNA Conjugates Market- Segmentation Analysis:

The Global siRNA Conjugates Market is segmented on the basis of Therapeutic Area, Development Stage, Conjugate Type, End User, and Region.

The cardiovascular, central nervous system, chronic disease, oncology, and rare disease segments are key areas in the siRNA conjugates market, as these therapies are critical for precise gene silencing in complex conditions. Growing research and development efforts, along with the rising need for targeted treatments in these areas, are driving demand. For instance, in 2023, according to the review on the global cell and gene therapy landscape by NIH Govt., more than 100 advanced gene, cell, and RNA therapy products were approved worldwide, with over 3,700 additional therapies in clinical and preclinical development, reflecting a significant expansion in innovative treatment development compared with previous years. The review highlights that by the end of 2023, the global pipeline of advanced therapeutic candidates encompassed thousands of programs across gene, cell, and RNA modalities. These trends highlight the rapid growth of siRNA conjugates and precision medicine globally.

From a usage perspective, hospitals, research institutes, and specialty clinics play a key role in the siRNA conjugates market due to their capacity for patient care, clinical trials, and specialized treatments. Hospitals enable broad therapeutic application and administration of siRNA-based therapies, while research institutes focus on discovery, development, and optimization of new conjugates. For instance, in 2023, according to the European Commission, there were about 2.3 million hospital beds available across the European Union, with an average of 511 beds per 100,000 inhabitants-figures reflecting the distribution of care capacity across member states. Between 2013 and 2023, EU hospital beds fell by ~7%, though countries like Portugal, Spain, and Romania saw slight per-capita increases. This underscores the importance of healthcare infrastructure in advancing siRNA conjugate therapies.

siRNA Conjugates Market- Geographical Insights

By region, the siRNA conjugates market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America's significant position in the market is due to advanced healthcare infrastructure, research capabilities, and high adoption of precision medicine. Rising demand for targeted therapies, growing investment in RNA-based treatments, and supportive regulatory frameworks reinforce the region's prominent role. For instance, in June 2025, according to the US govt., over 120 global clinical trials of RNA cancer vaccines are underway across melanoma, pancreatic, brain, lung, and breast cancers, reflecting increased research activity. By mid-2025, RNA cancer vaccines showed breakthrough results, including a 44% reduction in melanoma recurrence and immune responses in other cancers. These developments underscore North America's leadership in the siRNA conjugates market, driven by advanced infrastructure, robust research, and significant progress in RNA-based therapies.

The Asia-Pacific region is expanding due to rising healthcare spending and greater awareness of advanced therapeutic modalities. For instance, in 2023, according to IBEF.org, India's healthcare sector was valued at about US $372 billion, having grown substantially over recent years and supported by both public and private expansion. IBEF highlights that in 2024-25, the healthcare workforce in India exceeded 6 million professionals, and the government allocated nearly Rs. 99,858 crore (US $11.50 billion) to the sector in the Union Budget for 2025-26. As a result, these factors highlight the Asia-Pacific region's growing role in advancing healthcare and adoption of advanced therapies, supported by investment and workforce expansion.

Europe siRNA Conjugates Market- Country Insights

Europe is enhancing its role in the siRNA conjugates market, driven by joint research initiatives, aligned regulatory standards, and increased focus on RNA-based innovations. For instance, in April 2024, Wave Life Sciences Ltd. (Singapore/Europe) advanced its RNA medicines platform with multiple siRNA and RNA editing programs, including its GalNAc-conjugated INHBE siRNA (WVE-007) entering clinical development and expanded trials for its RNA editing candidate (WVE-006) in alpha-1 antitrypsin deficiency-highlighting growing innovation and clinical momentum in RNA-based therapeutics. These developments underscore Europe's growing leadership in siRNA therapeutics, driven by innovation, clinical progress, and collaborative research efforts.

siRNA Conjugates Market- Competitive Landscape:

The siRNA conjugates market is highly competitive, with key players like Alnylam Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Silence Therapeutics plc, Dicerna Pharmaceuticals, Inc., Wave Life Sciences Ltd., Sirnaomics, Inc., and Quark Pharmaceuticals, Inc. driving innovation in targeted therapies. These companies focus on enhancing precision delivery, improving efficacy, and minimizing off-target effects across multiple therapeutic areas. Investments in partnerships, R&D, and clinical trials are expanding pipelines and advancing next-generation siRNA technologies. In August 2024, Sirnaomics, Inc. entered a strategic partnership with Gore Range Capital LLC to establish Sagesse Bio, Inc., a joint venture aimed at advancing its RNAi therapeutics into aesthetic medicine and accelerating clinical development of its lead siRNA candidates for body contouring and focal fat reduction, highlighting a broader push to expand RNA-based innovations into new therapeutic areas.

Recent Developments:

In 2025, Arrowhead Pharmaceuticals, Inc. announced the FDA approval and commercial launch of REDEMPLO(R) (plozasiran) - its first-ever marketed siRNA therapeutic for adults with familial chylomicronemia syndrome, marking the company's transition from development to commercial availability of targeted RNAi medicines.

In June 2025, Sinopep-Allsino Biopharmaceutical Co., Ltd. entered into a strategic cooperation agreement with Vazyme, establishing a joint venture to advance synthetic biology platforms and expand technological capabilities in biopharma applications.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SIRNA CONJUGATES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

• WuXi XDC
• Creative Biogene
• Bachem
• LGC Biosearch Technologies
• Sinopep
• Organix
• CD Formulation
• Hitgen
• Alnylam Pharmaceuticals, Inc.
• Amerigo Scientific
• BOCSCI Inc.
• Creative Biolabs
• Bio-Synthesis Inc
• Creative Peptide
• GenScript
• Suzhou Biosyntech
• Arrowhead Pharmaceuticals, Inc.
• Silence Therapeutics plc
• Dicerna Pharmaceuticals, Inc.
• Wave Life Sciences Ltd.
• Sirnaomics, Inc.
• Quark Pharmaceuticals, Inc.
• Others

GLOBAL SIRNA CONJUGATES MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2020 - 2033

• Rare Disease
• Oncology
• Chronic Disease
• Central Nervous System
• Cardiovascular

GLOBAL SIRNA CONJUGATES MARKET, BY DEVELOPMENT STAGE- MARKET ANALYSIS, 2020 - 2033

• Clinical Trials
• Phase I
• Phase II
• Phase III
• Commercial
• Preclinical
• In Vivo
• In Vitro

GLOBAL SIRNA CONJUGATES MARKET, BY CONJUGATE TYPE- MARKET ANALYSIS, 2020 - 2033

• Peptide
• Lipid Nanoparticle
• GalNAc

GLOBAL SIRNA CONJUGATES MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

• Specialty Clinics
• Research Institutes
• Hospitals

GLOBAL SIRNA CONJUGATES MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• The Netherlands
• Sweden
• Russia
• Poland
• Denmark
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Indonesia
• Thailand
• Philippines
• Taiwan
• Vietnam
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Turkey
• Algeria
• Egypt
• Iran
• Qatar
• Rest of MEA

Table of Contents

1. siRNA Conjugates Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. siRNA Conjugates Market Snippet by Therapeutic Area
  • 2.1.2. siRNA Conjugates Market Snippet by Development Stage
  • 2.1.3. siRNA Conjugates Market Snippet by Conjugate Type
  • 2.1.4. siRNA Conjugates Market Snippet by End User
  • 2.1.5. siRNA Conjugates Market Snippet by Country
  • 2.1.6. siRNA Conjugates Market Snippet by Region
• 2.2. Competitive Insights

3. siRNA Conjugates Key Market Trends

• 3.1. siRNA Conjugates Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. siRNA Conjugates Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. siRNA Conjugates Market Opportunities
• 3.4. siRNA Conjugates Market Future Trends

4. siRNA Conjugates Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. siRNA Conjugates Market : Impact of Escalating Geopolitical Tensions

• 5.1. Impact of COVID-19 Pandemic
• 5.2. Impact of Russia-Ukraine War
• 5.3. Impact of Middle East Conflicts

6. siRNA Conjugates Market Landscape

• 6.1. siRNA Conjugates Market Share Analysis, 2025
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. siRNA Conjugates Market - By Therapeutic Area

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Therapeutic Area, 2025 & 2033 (%)
  • 7.1.2. Rare Disease
  • 7.1.3. Oncology
  • 7.1.4. Chronic Disease
  • 7.1.5. Central Nervous System
  • 7.1.6. Cardiovascular

8. siRNA Conjugates Market - By Development Stage

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Development Stage, 2025 & 2033 (%)
  • 8.1.2. Clinical Trials
    • 8.1.2.1. Phase I
    • 8.1.2.2. Phase II
    • 8.1.2.3. Phase III
  • 8.1.3. Commercial
  • 8.1.4. Preclinical
    • 8.1.4.1. In Vivo
    • 8.1.4.2. In Vitro

9. siRNA Conjugates Market - By Conjugate Type

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Conjugate Type, 2025 & 2033 (%)
  • 9.1.2. Peptide
  • 9.1.3. Lipid Nanoparticle
  • 9.1.4. GalNAc

10. siRNA Conjugates Market - By End User

• 10.1. Overview
  • 10.1.1. Segment Share Analysis, By Development Stage, 2025 & 2033 (%)
  • 10.1.2. Specialty Clinics
  • 10.1.3. Research Institutes
  • 10.1.4. Hospitals

11. siRNA Conjugates Market - By Geography

• 11.1. Introduction
  • 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
• 11.2. North America
  • 11.2.1. Overview
  • 11.2.2. siRNA Conjugates Key Manufacturers in North America
  • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.2.4. North America Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
  • 11.2.5. North America Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
  • 11.2.6. North America Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
  • 11.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.2.8. U.S.
    • 11.2.8.1. Overview
    • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.2.8.3. U.S. Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.2.8.4. U.S. Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.2.8.5. U.S. Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.2.9. Canada
    • 11.2.9.1. Overview
    • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.2.9.3. Canada Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.2.9.4. Canada Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.2.9.5. Canada Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.2.9.6. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
• 11.3. Europe
  • 11.3.1. Overview
  • 11.3.2. siRNA Conjugates Key Manufacturers in Europe
  • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.3.4. Europe Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
  • 11.3.5. Europe Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
  • 11.3.6. Europe Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
  • 11.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.8. Germany
    • 11.3.8.1. Overview
    • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.8.3. Germany Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.3.8.4. Germany Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.3.8.5. Germany Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.3.8.6. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.9. UK
    • 11.3.9.1. Overview
    • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.9.3. UK Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.3.9.4. UK Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.3.9.5. UK Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.3.9.6. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.10. France
    • 11.3.10.1. Overview
    • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.10.3. France Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.3.10.4. France Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.3.10.5. France Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.3.10.6. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.11. Italy
    • 11.3.11.1. Overview
    • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.11.3. Italy Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.3.11.4. Italy Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.3.11.5. Italy Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.3.11.6. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.12. Spain
    • 11.3.12.1. Overview
    • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.12.3. Spain Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.3.12.4. Spain Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.3.12.5. Spain Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.3.12.6. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.13. The Netherlands
    • 11.3.13.1. Overview
    • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.13.3. The Netherlands Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.3.13.4. The Netherlands Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.3.13.5. The Netherlands Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.14. Sweden
    • 11.3.14.1. Overview
    • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.14.3. Sweden Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.3.14.4. Sweden Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.3.14.5. Sweden Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.3.14.6. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.15. Russia
    • 11.3.15.1. Overview
    • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.15.3. Russia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.3.15.4. Russia Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.3.15.5. Russia Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.3.15.6. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.16. Poland
    • 11.3.16.1. Overview
    • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.16.3. Poland Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.3.16.4. Poland Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.3.16.5. Poland Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.3.16.6. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.17. Denmark
    • 11.3.17.1. Overview
    • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.17.3. Poland Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.3.17.4. Denmark Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.3.17.5. Denmark Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.3.17.6. Denmark Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.18. Rest of Europe
    • 11.3.18.1. Overview
    • 11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.18.3. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.3.18.4. Rest of the Europe Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.3.18.5. Rest of the Europe Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.3.18.6. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
• 11.4. Asia Pacific (APAC)
  • 11.4.1. Overview
  • 11.4.2. siRNA Conjugates Key Manufacturers in Asia Pacific
  • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.4.4. APAC Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
  • 11.4.5. APAC Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
  • 11.4.6. APAC Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
  • 11.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.8. China
    • 11.4.8.1. Overview
    • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.8.3. China Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.4.8.4. China Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.4.8.5. China Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.4.8.6. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.9. India
    • 11.4.9.1. Overview
    • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.9.3. India Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.4.9.4. India Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.4.9.5. India Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.4.9.6. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.10. Japan
    • 11.4.10.1. Overview
    • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.10.3. Japan Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.4.10.4. Japan Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.4.10.5. Japan Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.4.10.6. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.11. South Korea
    • 11.4.11.1. Overview
    • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.11.3. South Korea Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.4.11.4. South Korea Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.4.11.5. South Korea Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.12. Australia
    • 11.4.12.1. Overview
    • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.12.3. Australia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.4.12.4. Australia Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.4.12.5. Australia Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.4.12.6. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.13. Indonesia
    • 11.4.13.1. Overview
    • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.13.3. Indonesia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.4.13.4. Indonesia Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.4.13.5. Indonesia Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.4.13.6. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.14. Thailand
    • 11.4.14.1. Overview
    • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.14.3. Thailand Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.4.14.4. Thailand Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.4.14.5. Thailand Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.4.14.6. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.15. Philippines
    • 11.4.15.1. Overview
    • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.15.3. Philippines Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.4.15.4. Philippines Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.4.15.5. Philippines Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.16. Taiwan
    • 11.4.16.1. Overview
    • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.16.3. Taiwan Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.4.16.4. Taiwan Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.4.16.5. Taiwan Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.4.16.6. Taiwan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.17. Vietnam
    • 11.4.17.1. Overview
    • 11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.17.3. Vietnam Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.4.17.4. Vietnam Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.4.17.5. Vietnam Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.4.17.6. Vietnam Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.18. Rest of APAC
    • 11.4.18.1. Overview
    • 11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.18.3. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.4.18.4. Rest of APAC Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.4.18.5. Rest of APAC Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.4.18.6. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
• 11.5. Latin America (LATAM)
  • 11.5.1. Overview
  • 11.5.2. siRNA Conjugates Key Manufacturers in Latin America
  • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.5.4. LATAM Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
  • 11.5.5. LATAM Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
  • 11.5.6. LATAM Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
  • 11.5.7. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5.8. Brazil
    • 11.5.8.1. Overview
    • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.8.3. Brazil Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.5.8.4. Brazil Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.5.8.5. Brazil Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5.9. Mexico
    • 11.5.9.1. Overview
    • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.9.3. Mexico Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.5.9.4. Mexico Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.5.9.5. Mexico Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5.10. Argentina
    • 11.5.10.1. Overview
    • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.10.3. Argentina Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.5.10.4. Argentina Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.5.10.5. Argentina Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5.11. Colombia
    • 11.5.11.1. Overview
    • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.11.3. Colombia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.5.11.4. Colombia Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.5.11.5. Colombia Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5.12. Rest of LATAM
    • 11.5.12.1. Overview
    • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
• 11.6. Middle East and Africa (MEA)
  • 11.6.1. Overview
  • 11.6.2. siRNA Conjugates Key Manufacturers in Middle East and Africa
  • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.6.4. MEA Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
  • 11.6.5. MEA Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
  • 11.6.6. MEA Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
  • 11.6.7. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.8. Saudi Arabia
    • 11.6.8.1. Overview
    • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.9. United Arab Emirates
    • 11.6.9.1. Overview
    • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.10. Israel
    • 11.6.10.1. Overview
    • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.10.3. Israel Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.6.10.4. Israel Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.6.10.5. Israel Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.6.10.6. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.11. Turkey
    • 11.6.11.1. Overview
    • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.11.3. Turkey Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.6.11.4. Turkey Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.6.11.5. Turkey Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.12. Algeria
    • 11.6.12.1. Overview
    • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.12.3. Algeria Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.6.12.4. Algeria Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.6.12.5. Algeria Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.13. Egypt
    • 11.6.13.1. Overview
    • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.13.3. Egypt Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.6.13.4. Egypt Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.6.13.5. Egypt Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.14. Iran
    • 11.6.14.1. Overview
    • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.14.3. Iran Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.6.14.4. Iran Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.6.14.5. Iran Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.6.14.6. Iran Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.15. Qatar
    • 11.6.15.1. Overview
    • 11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.15.3. Qatar Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.6.15.4. Qatar Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.6.15.5. Qatar Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.6.15.6. Qatar Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.16. Rest of MEA
    • 11.6.16.1. Overview
    • 11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.16.3. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.6.16.4. Rest of MEA Market Size and Forecast, By Development Stage, 2020 - 2033 (US$ Million)
    • 11.6.16.5. Rest of MEA Market Size and Forecast, By Conjugate Type, 2020 - 2033 (US$ Million)
    • 11.6.16.6. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- siRNA Conjugates Industry

• 12.1. Competitive Benchmarking
  • 12.1.1. Competitive Dashboard
  • 12.1.2. Competitive Positioning
• 12.2. Company Profiles
  • 12.2.1. WuXi XDC
  • 12.2.2. Creative Biogene
  • 12.2.3. Bachem
  • 12.2.4. LGC Biosearch Technologies
  • 12.2.5. Sinopep
  • 12.2.6. Organix
  • 12.2.7. CD Formulation
  • 12.2.8. Hitgen
  • 12.2.9. Alnylam Pharmaceuticals, Inc.
  • 12.2.10. Amerigo Scientific
  • 12.2.11. BOCSCI Inc.
  • 12.2.12. Creative Biolabs
  • 12.2.13. Bio-Synthesis Inc
  • 12.2.14. Creative Peptide
  • 12.2.15. GenScript
  • 12.2.16. Suzhou Biosyntech
  • 12.2.17. Arrowhead Pharmaceuticals, Inc.
  • 12.2.18. Silence Therapeutics plc
  • 12.2.19. Dicerna Pharmaceuticals, Inc.
  • 12.2.20. Wave Life Sciences Ltd.
  • 12.2.21. Sirnaomics, Inc.
  • 12.2.22. Quark Pharmaceuticals, Inc.
  • 12.2.23. Others

13. 360 Degree AnalystView

14. Appendix

• 14.1. Research Methodology
• 14.2. References
• 14.3. Abbreviations
• 14.4. Disclaimer
• 14.5. Contact Us